Friday, September 30, 2011
by Lyle Fettig
The Journal of Clinical Oncology published a Swedish study which examines correlation between patients being informed of imminent death status and other palliative care quality outcome measures. In the study, 91% of patients were informed of their imminent death status. How was this measured? Sweden has a national palliative care registry which is described in the study text (click the little Union Jack at the top right of the page to view the front page in English) :
This online register was completed by the physician and/or nurse responsible for the patient's care during the last week of life, although HCPs were not aware of the research question of this study. The design of the SRPC Web questionnaire does not allow any missing data at submission. The Web questionnaire is based on the 11 principles constituting good death as defined by the British Geriatrics Society and was designed to be used in any care setting, independent of diagnosis, with the intent to look retrospectively at important aspects of care delivered during the last week of life. The 25 items on the SRPC include 14 questions that cover background data of patient and reporting unit and three questions that cover items not considered relevant to the aim of this study (ie, use of visual analog or numeric rating scales during last week of life, frequency of pressure ulcers, and staff reflection). The remaining eight questions covering, for example, degree of autonomy, information about imminent death, symptom control, parenteral as needed (ie, pro re nata or PRN) prescriptions, and preferred location at time of death, were included in the analysis in this study.The ACP Hospitalist Blog commented on this study in more detail right after the study was released. I'm going to keep my comments on the results brief. The bottom line was no surprise. Being informed of imminent death status correlated positively with more prn symptomatic medication orders, family being informed of imminent death status as well as being offered bereavement services, and patients recorded as dying in their preferred location. Being informed did not correlate with increased anxiety or pain. Minor methodological issues aside, this is yet more data (need we more?) to suggest that we should get over the worry about the effect of prognostic information on patients, even at the very end. When we don't sensitively explore patients' wishes for prognostic information and then give them info when they want it, it's usually because of our own discomfort rather than a protective effect for the patient.
What really strikes me about this study though is the existence of the database which made the study possible. Considering the fact that I would struggle to access many of these data at my own institution, it's amazing that Sweden has a national database and that over 13,000 subjects could be included in the study. Sweden is not unique in their attempt to measure various outcomes on a population level near the end of life. See this Canadian study looking at the trajectory of performance status and symptom scores in patients with cancer in the last six months of life.
Would something like this be possible in the United States? Could we develop a common repository for palliative care outcome measurement for individual patients? What are the true patient-centered outcomes which matter most to our patients and families when confronted with serious illness?
These questions don't exist in a vacuum and should be viewed within the context of the Accountable Care Act and evolving healthcare system. The Department of Health and Human Services recently released final rules for Accountable Care Organizations. The rules document describes 33 quality outcomes which ACO's will need to report in order to qualify for "shared savings" above and beyond Medicare Part A and B reimbursements (see page 324). In the first year of the program, merely reporting all 33 outcomes will be sufficient to qualify for the "shared savings" payments. In subsequent years, the ACO will need to meet a certain standard to qualify.
Take note of the first ten quality outcomes (all but the last three will be measured by patient survey data):
- Getting Timely Care, Appointments, and Information
- How Well Your Doctors Communicate
- Patients' Rating of Doctor
- Access to Specialists
- Health Promotion and Education
- Shared Decision Making
- Health Status/Functional Status
- Risk-Standardized, All Condition Readmission
- Ambulatory Sensitive Conditions Admissions: Chronic Obstructive Pulmonary Disease
- Ambulatory Sensitive Conditions Admissions: Congestive Heart Failure
While I'm rambling on about everything under the sun, the Swedish Palliative Care Registry has a second questionairre that is filled out yearly at a program level (rather than specific to individual patients). We do already have a registry similar to this: The CAPC National Palliative Care Registry. Your program should sign up for that, too, if it hasn't already.
Friday, September 30, 2011 by Lyle Fettig ·
Tuesday, September 13, 2011
by Holly Yang
On September 1st 2011, the Joint Commission started certifying hospital-based Palliative Care Programs! It is open to all Joint Commission accredited hospitals including long-term acute care care and children's hospitals. The standards for certification were based on the National Consensus Project's Clinical Practice Guidelines for Palliative Care and A National Framework and Preferred Practices for Palliative and Hospice Care Quality from the National Quality Forum. For previous comments on the importance of this see Christian's post from spring when it was announced.
It is "designed to recognize hospital inpatient programs that demonstrate exceptional patient and family-centered care in order to optimize the quality of life for patients with serious illness. Palliative care involves addressing physical, emotional, social and spiritual needs and facilitating patient autonomy, access to information and choice."
The full text is here, but some of the highlights of the requirements are (I'm paraphrasing, so please see the complete text for all the little words that make a big difference):
- 24/7 coverage - by phone on nights and weekends, with availability of someone to come in to see the patient if necessary, and "must be able to provide the same level of palliative care services during nights/weekends as during normal weekday hours."
- See patients - At least 10 in the past and at least one during the on-site review
- Use evidenced-based approach to guide care (and/or practice guidelines to deliver care using a standardized method)
- Have the ability to direct clinical management and coordinate care
- Have an IDT (interdisciplinary team) and follow an organized approach to deliver care
- QI - Improve performance by collecting performance measurement data over time (at least 4 months' worth). No specific tools, but should be "evidenced-based, relevant, valid and reliable"
Tuesday, September 13, 2011 by Holly Yang, MD ·
Monday, August 1, 2011
Eric Widera over at GeriPal posted in April about changes in the National Resident Matching Program (NRMP) timeline for medical subspecialty fellowships, and the implications for Hospice and Palliative Medicine (HPM) and Geriatrics.


So, I ask for and get extensions of the offers. I interview at the program close to my wife's family. When I meet with the program director, I'm told their decision about my cohort of applicants will likely be made after my other offer extensions are up. I also get what is probably a generic invitation to contact the program if I needed an early decision to clarify matters. So, back to the offering programs to update them and ask for more time, which they graciously grant. I then ask for, but did not get, an early decision, which means I was still in the running. So, I am being pulled now in at least three ways, with irons still in the fire.
Interviewing is expensive, especially on a resident's salary, and doing this all during residency, with long hours while taking care of patients and collateral responsibilities, and having to use vacation time is all very stressful. As this is all going on interview offers continue to trickle in. I begin to turn down interview offers, even canceling interviews I already have scheduled, thinking I am likely to take one of these positions. At the same time, I am anxious about eliminating interviews out here in the Wild, Wild West because something could go wrong and my birds in the bush could fly the coop, and the whole thing could come down like a house of cards leaving me in the cold, and empty-handed.
The last few days start ticking down. Out of the blue, I get a contingent offer from a program that is very strong clinically and highly academic, in a culturally vibrant town, not too terribly far away from my family. They are working on getting approval for another Accreditation Council for Graduate Medical Education (ACGME) slot, versus perhaps another candidate may turn down an offer they have already made. At this point I make criteria for being "drawn and quartered," now being pulled in four different directions. The opportunity costs mount!

The way it felt, both as it was happening and in retrospect, was something like an uncertain, perilous and epic quest. It reminded me of my favorite epic, The Odyssey. Odysseus was struggling to get home after many long years away, but one problem after another cropped up to thwart him: the whim and malice of gods and goddesses, the threats of monsters, the thrall of enchantments, the lure of comfortable captivities, the sirens' call, tempestuous storms and even more monsters. It is at this point that imagery from the Odyssey wells up: Odysseus caught between the gorging and belching vortex of Charybdis on the one hand and the rapacious heads and voracious mouths of Scylla on the other, with no way out but through.

By luck and craftiness Odysseus barely averts disaster again and again, and by holding to the course, he finally achieves his quest and arrives home, travel-weary, older, perhaps wiser… but also with an unnecessary case of PTSD. To reason that since the hero survives and achieves the quest, the arduous and circuitous course he was made to take is justified is, in my opinion, a rationalization.

In the end, I secured a position and I am very happy with my outcome. I am however very unhappy with the process. Thank goodness for the Electronic Resident Application System (ERAS) where one's application, CV, personal statement, letters of recommendation, are uploaded into the electronic ERAS cloud once, and then are electronically submitted to one's desired programs (except for the programs that don't participate in ERAS and require old-fashioned paper applications, thus duplicating work for interested applicants and their recommenders). Having ERAS in place prevented the process from being even more labor-intensive and chaotic.
The diversity among programs in their respective timelines for application review, interviewing, and how and when to do what about making offers is frankly stunning. My process was cut short by a spoils-to-the-swift ethic. Because of the asynchronous timelines, I had to decline interview offers from programs I was very interested in. Given the inherent power disparity in the roles and the dynamics involved, I did not believe I had the latitude to walk away from offers from great programs in order to "explore my options" further. Perhaps my issue, but I doubt mine alone.
If there wasn't already an existing, simple, validated, large-scale, low-cost system to regulate and standardize behavior and decision-making among applicants and programs then one would be pragmatically stuck with the status quo. Luckily for us the kinks and bugs have already been worked out and a process is readily available for us to plug into. I'm speaking of course of the NRMP, or more simply "the Match."
Having been through an NRMP Match, and now this Matchless Meet Market, I find the latter is wholly unsavory and unsatisfactory. Rather than feeling like I've come through a fair process conducted on an even playing field to arrive at an optimized placement to advance my learning and professional development and to staff the houses of programs with the best they can attract, instead I feel like I just bought a house in today's market; I've closed the best deal I could, but I really would not want to do that over again.
Furthermore, I believe I was extremely lucky; my timelines were generous and fluid. I just think about those souls out there who are waiting for an interview in their preferred program, near their family, but get an acceptance from another program with a one week deadline to accept the offer (not an uncommon demand). Yes, I feel lucky for how it turned out in the end, but I also feel like I've been through the wringer unnecessarily, and I resent that.
My conclusion is that for the sake of learners (and I actually believe in the interests of most programs) HPM needs to align with the leaders in GME and participate in The Match on the same timeline as the other medical specialties. Incidentally, moving the process into applicants' final year of specialty training would bring it in line with the fellowship application process in other specialties, at least with Physical Medicine & Rehabilitation and Emergency Medicine.
If you have a war story, please feel free to add it. I would suggest de-identifying the data for the sake of human subjects protection, if you get my drift.
[Ed. Note: In the vast palliative care social media echo chamber, Eric Widera over at the GeriPal has provided the 2 to a 1-2 post combination on the problems of applicant/learners in the current state-of-the-fellowships. Please be sure to pop on over and check it out. - McMichael
And after you read that, you can see Christian Sinclair's alternate take on the Geripal post. - Sinclair]
Monday, August 1, 2011 by Brian McMichael, M.D. ·
Monday, July 25, 2011
If you are a med ed geek like me, you L-O-V-E the Interactive Educational Exchange which has been a fun and exciting part of the Americal Academy of Hospice and Palliative Medicine (AAHPM) Annual Assembly for the past two years. It's not your ordinary concurrent session. No! Instead, you listen to a quick overview of the different presentations and then you zip around to learn more about the ones that you find most intriguing. I have always come away with at least one interesting idea to try or tweek to fit my teaching style and audience. So... if you're students are yawning, you can A) buy them coffee or B) go to the Interactive Educational Exchange on March 9th, 2012 from 3:30 to 5:00 pm.
If you've got an exciting way to teach palliative medicine to any discipline, please do share! Submit it for the 2012 Interactive Educational Exchange at the AAHPM Annual Assembly in Denver! Hurry! Submissions are due by 5 pm PST August 2, 2011! Heck! They make it easy by even giving you previous year's submission examples.
Hope to see you there!!!
![]() |
| Photo by Elizabeth Thomsen via Flickr |
Monday, July 25, 2011 by Holly Yang, MD ·
by Holly Yang, MD ·
Tuesday, July 19, 2011
I've been following the emergence of denosumab as a preventive therapy for skeletal related events in patients with bone metastases, and thought I'd write about it. Denosumab is a monoclonal antibody therapy which binds RANK-ligand, leading to osteoclast inhibition, decreased bone turnover, and presumably its salutary effects in preventing fractures and other skeletal related events (this glowing editorial on denosumab gives a nice/brief overview of its mechanism of action - the image is from this editorial.)
There have been several publications the last half-year in Journal of Clinical Oncology (breast cancer study here; myeloma & non-breast, non-prostate cancer study here) all showing that denosumab is non-inferior to zoledronic acid in preventing skeletal related events. (SREs are a composite research outcome which combines pathologic fracture, hypercalcemia, and need for surgery/radiotherapy due to bone mets.) I'd noted the abstracts, and already seen a few patients receiving it, but finally gave the research a closer look the last couple weeks.
What struck me, as I read the paper for the myeloma/non-breast/prostate one, was their power calculation: they calculated needing 1700 patients to demonstrate noninferiority of denosumab to zoledronic acid given monthly. That's a pretty high number for a supportive cancer trial, I thought to myself, Why? Well the answer is obvious, and borne out by the study results. The benefits of denosumab, compared to zoledronic acid, are marginal, and you'd need a lot of patients to minimally prove statistical significance: denosumab met their non-inferiority definition; the median time to first on-study SRE was 20.6 months for denosumab vs 16.3 months for zoledronic acid (this difference did not achieve statistical significance). There was some expected differences in side effects: more flu-like symptoms and renal problems with zoledronic acid, some more hypocalcemia with denosumab. That's about it. The breast cancer study had similar findings, a little more positive (by 27 months 50% of patients in the zoledronic acid group had had an SRE whereas only 40% of of the denosumab group had - this met their superiority criteria). The paper doesn't present its data in a way that allows one to calculate this exactly, but by eye-balling a figure (2a) my conclusion is that the number needed to treat to prevent 1 SRE over 27 months is 10 (you'd have to give denosumab to 10 patients to further prevent a single SRE over 27 months compared to what you would have prevented with zoledronic acid).
This is a modest enough improvement that the investigators needed 2000 patients in the breast cancer study to demonstrate it actually is, and not noise. I want to be clear: I think the research supports that denosumab is as good as zoledronic acid, and for breast cancer patients it is better. I don't doubt that. That's what the N of 2000 showed. The issue is, as a clinician, I have become more and more inclined over the years to think that the bigger N you need to show something, chances are that something is of a magnitude that is small enough, or of a frequency that is rare enough, that it's an intervention that is likely to help any given patient in theory only. The 'better' of denosumab is probably barely worth it, at least for most patients (it may be worth it for patients with significant chronic kidney disease, but that's it).
Part of this is then re-learning what was beaten into me when I was younger, which is that bigger trials are better. They probably are better if the outcome you're interested in is a small improvement, or rare event (and there are some outcomes for which that's appropriate - stroke prevention, for instance), but if the outcome you're interested in is anything else, including symptom control, you want something better than a small, barely statistically demonstrable, improvement.
Another way of looking at this are the costs involved. I tried finding out more about this, and found a couple cost-effectiveness analyses (here, here - both from 2011 ASCO), dishearteningly brought to us by Novartis, the maker of zoledronic acid. Yep. You can see Amgen (the maker of denosumab, and palifermin) & Novartis glowering at each other across the aisle at the poster session of ASCO. Both suggest that denosumab costs an additional $640,000 dollars per quality-adjust life year gained in breast cancer. More for prostate cancer. Denosumab's acquisition cost is $1650/dose vs $887/dose for zoledronic acid. Ignoring arguments about QALYs (I'm not the biggest fan either), the magnitude of the dollar figure here gives you some sense of how marginal the improvement denosumab is bringing. One wonders about all the ways one could use that money to help our patients in ways that will be actually helpful to them.
Which brings me to palifermin to prevent oral mucositis. A recent JCO published the results of two (related, and Amgen funded, and randomized, double-blinded, placebo controlled) trials of weekly palifermin times 7 doses during definitive radiochemotherapy for head and neck cancer: here & here. Palifermin is a recombinant human keratinocyte growth factor, and is approved for the prevention of oral mucositis for patients undergoing stem cell transplants. Revisiting my prior discussions, both studies estimated they needed ~200 patients to be adequately powered to demonstrate superiority of palifermin over placebo in preventing the incidence of severe oral mucositis (200 patients - now that's a study which is probably measuring something!).. Rates of severe OM were reduced by ~15% (absolute risk reduction - NNT of 6.7). Secondary outcomes suggested a (dramatic but apparently non-statistically significant) trend in one study and a statistically significant reduction in the other of duration of severe OM by two weeks. Acknowledging that that's a sort of 'wow' outcome that gets one excited, I have to remind myself it was a secondary outcome. Going through definitive radiochemotherapy for head and neck cancer has got to be one of the harshest medical interventions around, and reducing the most severe OM by a couple weeks seems huge. Notably, however, they didn't look at health related quality of life, and one wonders if this was a missed opportunity. I've tried to identify cost effectiveness analyses for palifermin, but haven't found any for radiochemotherapy. The stem-cell transplant literature suggests it's cost effective in that setting.
Tuesday, July 19, 2011 by Drew Rosielle MD ·
Wednesday, June 29, 2011
Palliative Care still befuddles many people when they first hear the term. Even after seeing it people may feel like the many blind scientists touching different parts of an elephant. Historically we have described to people what palliative care is on our terms as the experts who provide it. Looking at many organizations definition of palliative care they have not been made based on public opinion and understanding.
The Center to Advance Palliative Care (CAPC) with support from the American Cancer Society Action Network commissioned a study of public opinions on palliative care, but now the question is what can we do with this new information.
Before I get any further on my opinion of the key findings, I need to tell you to take 15 minutes and read the actual report. Then go talk to your team and your leadership about this. It needs to be discussed and understood widely by all stakeholders. Do it, I mean it (and then come back here abnd post what you talked about so we can all learn).
The key findings:
Concerns for quality of care for patients with serious illness, which include:
- treatment choices not offered
- lack of physician collaboration
- lack of confidence in plan after leaving the clinic or hospital
- lack of control
- lack of time
- lack of listening
People do not know what palliative care is. 78 % of people said they were 'not at all knowledgeable or don't know' when asked about palliative care. Frustrating I am sure to those of you who beat the drum everyday but at least it is not being wholly defined and understood without us (yet).
Physicians equate palliative care with hospice or end of life care.Well think about it...many in the field nearly always refer to hospice AND palliative medicine, (although I think this is changing a bit and read to the end for more) so isn't that like peanut butter and jelly? They have to go together right? (H/T @aliciabloom)
Think about palliative care consults in the hospital which is where most docs are exposed to palliative care. What does a palliative care team get asked to do? Consults for goals of care discussion when other options have been exhausted, even though palliative care wants and could be involved much further upstream and some institutions are successful at doing this. So of course many docs would consider palliative care 'brink of death' care. Which leads people to think 'hospice in the hospital' which I have heard whilst cringing too many times...
'Serious Illness' is perceived as less about 'being terminal' than 'Advanced Illness' (18% v 36%)
So who is your palliative care team looking to serve...those with serious or advanced illness. Whichever it is, I think we need to have consistency across the board. Our two major representative organizations are on the same page at least. (HPNA did not mention patients, but focused more on support of nurses in their mission statement)
AAHPM's Core Purpose:Are all of our member organizations and constituents using similar language? Is uniformity a important goal? I think so.
To improve the care of patients with life- threatening or serious conditions through advancement of hospice and palliative medicine.
NHPCO's Vision:
A world where individuals and families facing serious illness, death, and grief will experience the best that humankind can offer.
Palliative Care should be made available to patients with serious illness.
Once informed there were high rates (in the 90's) believing there should be access to pallaitive care for their loved ones, regardless of political affiliation (although there were some differences). To get patients access to quality palliative care, we need to be able to create a consumer demand especially if physicians are reluctant to consult. After we do that we need to quickly figure out the workforce issues. (Another blog post...)
Language Matters.
Now for the tricky part that really started me thinking about the conjoined twin nature of Hospice and Palliative Care. They took what was termed an 'old' definition (source unclear - must ask @DianeEMeier) and compared it to a new version (also source unclear). Italics highlight the new portions:
OLD: Palliative care is the medical specialty focused on improving the quality of life of people facing serious illness. Emphasis is placed on pain and symptom management, communication and coordinated care. Palliative care is appropriate from the time of diagnosis and can be provided along with curative treatment
NEW: Palliative care is specialized medical care for people with serious illnesses. This type of care is focused on providing patients with relief from the symptoms, pain, and stress of a serious illness - whatever the diagnosis. The goal is to improve quality of life for both the patient and the family. Palliative care is provided by a team of doctors, nurses, and other specialists who work with a patient's other doctors to provide an extra layer of support. Palliative care is appropriate at any age and at any stage in a serious illness, and can be provided together with curative treatment
Nothing totally revolutionary in the definitions except for the outcomes when they compared the acceptance/favorable rate for the two definition. Mean Rating Score (Scale of 100) improved from 63 to 74 and the % scoring it in the 75-100 range increased from 36% to 60%.
Personally I think the 'new' one is too long for saying in a clinical setting compared to the first, but maybe better for brochure language. Also to get people who refer to palliative care to introduce you to the family using the second definition will be pretty hard. Instead they are likely looking for something easy to say and memorable...like 'hospice in the hospital.' (which is not accurate for those of you with that misconception.)
But the part that got me thinking is this new definition really made me look at the 'can be provided with curative treatment' phrase. I have said it a million times, but now looking at it makes me think that hospice is becoming less of a type of palliative care since it has the emphasis on time via prognostic qualifications per the Medicare Hospice Benefit. I know the lumping or splitting the terms of hospice and palliative care is a topic of great debate in the field, so I want to let you know that these are my opinions and not those of the AAHPM board. But I really think we need to keep this as a open debate for our field. I don't think we are served by splitting the terms, but lumping is causing confusion.
So how will you use this research?
And a big kudos to the American Cancer Society Action Network for supporting this. The ACS is really working well with our key leadership orgs. Now if we could only get the NIH, NCI, and others to...
Wednesday, June 29, 2011 by Christian Sinclair ·
Not a good start from a newspaper that has actually been quite kind to hospice in the past. The rest of the article goes on to discuss the various fixes including every hospice medical director's new task: the face to face certification visit. (We have not yet dedicated a blog post to face-to-face home visits for certification, but one is in the works so we can has that out at a later date.)
But the article leaves out a lot and I feel it is pretty one-sided. Apparently Don Schumacher, head of the NHPCO, has found some flaws in the article too as he is communicating with the NYT editorial board. There is relatively little about potential changes to the payment structure to focus greater reimbursement during the first 7 and last 7 days of service when need is thought to be the greatest. The article does not talk about or reference the article by another NYT reporter from 2007 with the title "In Hospice Care, Longer Lives Mean Money Lost" about the aggregate cap. Nor did it quote the Duke Study that found hospice care saved Medicare an average of $2,300 per beneficiary (OPEN ACCESS PDF), calling hospice “a rare situation whereby something that improves quality of life also appears to reduce costs.” Yeah, they missed some stuff.
Which is not to say we need to look closely at fraud issues. Good oversight is important for a multi-billion part of the health care system, but we have to realize that every problem started out as the solution to another problem. The system is perfectly designed for the outcomes it gets. So let your legislators know about what hospice means to you. Talk to your organizations and actually answer the advocacy emails that moment instead of promising to get back to them later.
As the NYT usually does there is no ability to comment on the article but there is a linked blog post at "The New Old Age" which allows for comments. As of this writing there are 64 comments. Here are a few I thought stood out:
It is amusing and annoying to be complaining about the costs of hospice care, when in fact hospice patients are forgoing the ER visits, hospitalizations, specialists' visits, procedures, and many medications that Medicare would instead be covering if not for the patient making a decision to pursue comfort care only. So, what was the cost SAVINGS to Medicare by having these people on hospice, even though they stayed on longer than usual? Alot.- ras
I don't even believe desperate old people are gaming the system via hospice. But if they are, it's because this country has utterly failed them, taken payroll deductions for a lifetime in exchange for medical care in old age, and then only given the kind of medical care 70-year-olds need, not 90-year-olds. Shame on us. - jane gross
Hospice is a critical service that is offered to all. It is necessary, compassionate, and well run. So, if we discontinue it or cut services, we are a nation without merit and compassion. We will not only be third world, we should not be in this world. - Julie
The article disingenuously ignores this broader care issue while it exploits an example of an Alzheimer's patient. Please, NY Times, get perspective on the bigger picture. Help the US face its fear of dementia that keeps us in denial and prevents us from preparing to fight a huge healthcare tidal wave. Take more leadership and make a difference. - Suzanne
So it's too expensive to have an MD check on hospice patients once every six months? The health care industry has become even more shamelessly and barbaricly greedy than I thought. - Cowboy Marine
Photo credit: Flickr user: castle79
by Christian Sinclair ·
Sunday, June 19, 2011
Here is the video (link to original post):
Below are some of my favorite lines/segments because they emphasize the frustrating weaknesses of our current approach to care of the critically ill:
"His functional score is -2, which means death within minutes."There are other little gems I don't want to spoil that will make sense to anyone who has worked in the hospital, and for the non health care professionals reading this post I think anyone who has had a loved one critically ill will recognize some of these absurd situations that divorce the care of the numbers from the care of the patient. This point is highlighted in my favorite line of the video which is repeated over and over again from both the hospitalist and the ICU nurse:
'The cardiologist who orders a stat echo, EKG Q1 hour, and a iTunes enhanced pacemaker so he can bill for music therapy.'
"'Everyone deserves to die with a normal BMP."
"I'm taking care of him...but not really."
Listen all the way to the end to get a sense of what HH really thinks about palliative care in the hospital. He has been a big supporter of palliative care and he gets the fact that palliative care should be far upstream from just dying patients in the ICU. For examples see some of his other posts:
Barriers to Palliative and Hospice Care: Denied by the Nursing HomeEnd of Life Care Discussion Should Occur Before Death
The Power of Love: Going to Dialysis Hell and Back
Leave your thoughts here but also go to Happy Hospitalist's blog and leave comments there because it is pretty popular and our thoughts might get to people outside our normal blogging circles
Sunday, June 19, 2011 by Christian Sinclair ·
Many of you have probably heard in the past 2 months about the Modern Healthcare 35th Anniversary "Big Impact" Tournament from other hospice advocates imploring you to vote. I have advocated for it on Facebook and Twitter, but until now I had not really thought it important enough to dedicate a blog post on the subject. Frankly what does winning this online tournament mean? Clearly there is no prize money and if there was you would get your cut after me.
So is this about bragging rights? Who would we regale with our great stories about besting Patient Safety Advocacy in the second round? I think these are important questions that go beyond winning a popularity contest. If hospice champions and the everyday hospice professionals feel we are the most important innovation in the past 35 years, why in the world doesn't it feel that way when daily, we still have to overcome stigmas and mis-information about hospice care?
I realize I am asking more questions than answering but this supposedly playful tournament now has me thinking about the bigger stakes now that we have gotten this far for whatever that is worth. I'm not sure I will impress or convince anyone about the value of hospice when I tell them 'hospice care' won an online tournament of 64 different influential forces in American Health Care over the past 35 years. Heck we were even seeded 12th in the Innovations bracket!
Let's look at our track record thus far (seeds):
Round 1: Defeated (#5)New Models of Managed Care 56-44
Round 2: Defeated (#4) Patient-Safety Advocacy 57-43
Round 3: Defeated (#1) Electronic Health Records 61-39
Round 4: Defeated (#3) Clinical and Financial Performance Transparency 70-30 (Blowout!!)
Round 5: Defeated (#2 seed in the Events) Institute of Medicine's "To Err is Human" report 52-48 (Nail biter!)
Final Round: Voting open until June 24, 2011 against the #8 seed in Organizations - the Institute for Healthcare Improvement
Looking over this list, the tournament and open voting idea makes less sense. Hospice clearly has many more supporters or people who even get what hospice care is vs. 'New Models of Managed Care' so why didn't we stop them. Honestly hospice care is probably the concept most easily understood and the least reviled (Electronic Health Records! Everybody gets frustrated by their chippy, inconsistent play. Maybe they will gro w into a powerhouse in a few years when they actually get more efficient and the coaches understand how the game is played.)
So hopefully someone will tell me to relax it really means nothing, so I can stop asking questions that are really hard to answer. But truthfully, I want this to mean something. But it needs to mean more than a silly online tournament of health care wonks and Facebook fans voting for the sentimental favorite. If people really believe hospice care is the part of our health care system that has the biggest impact, then let's have something bigger to show for it.
Hospice care and more importantly the broader role for palliative care regardless of near death prognosis is something I believe in. So go vote* so we can win and then we can discuss what to do with it later...
Let's go purple and green!* Yes they will ask for your email. What they do with it I can't say since it is not clear from the site. You can vote once per day. Feel free to send to your staff and post on your hospice and personal Facebook pages as well as Twitter. Voting closes June 24th. Winner announced July 25th.
We got the winning team!
H-O-S-P-I-C-E - What does that spell?
CARING!!!!
by Christian Sinclair ·




